81597-52-6

Upstream product

• 55854-46-1 5-bromo-2-thiophenesulfonyl chloride 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 
• 53442-30-1 N-methyl-2-thiophenylsulfonamide 

Downstream Products

• 864961-50-2 5-bromothiophene-2-sulfonic acid [2-fluoro-2-(4-fluorophenyl)ethyl]-methyl-amide 
• 864961-46-6 5-Bromothiophene-2-sulfonic acid[2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide 
• 864961-48-8 5-Bromothiophene-2-sulfonic acid[2-(4-fluorophenyl)-2-methoxyethyl]-methyl-amide 
• 337536-13-7 5-[4-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]phenyl]-N-methyl-2-thiophenesulfonamide 
• 864961-45-5 5-Bromothiophene-2-sulfonic acid[2-(4-fluorophenyl)-2-oxoethyl]-methyl-amide 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: -(CH2)1-4-, (C2-C4)-alkenyl, (C2-C4)alkynyl, -S-(CH2)1-3-#, and -(CH2)1-3-O-#; wherein the symbol # indicates the position at which Xn is attached to R1; Yn is a birradical selected from the group consisting of: -(CH2)2-4-, -S-(CH2)1-3#, and -O-(CH2)1-3-#,; where in the symbol # indicates the position at which Yn is attached to R2; and R3 is a radical selected from the group consisting of: -OR4. The compounds of formula (I) are useful in the treatment of cancer

SUBSTITUTED BIPHENYL DERIVATIVE

The present invention relates to a biaryl derivative or a pharmacologically acceptable salt thereof having an excellent collagen-synthesis inhibition activity. A biaryl derivative having a structure represented by the following General Formula (I) or a pharmacologically acceptable salt thereof: wherein R1 represents a C6-C10 aryl group which is substituted with one to three group(s) each independently selected from the group consisting of a group defined by formula R-L-, a di-(C1-C6 alkyl)amino group, a di-(C1-C6 alkyl)aminosulfonyl group, a hydroxyaminocarbonyl group, and a halogen atom, and so on; R represents a C1-C6 alkyl group, and so on; L represents a sulfonyl group, an aminosulfonyl group, or a sulfonylamino group, and so on; R2 represents a hydrogen atom, and so on; A represents a group defined by formula (II), (III), or (IV); R3 represents a C1-C6 alkyl group, and so on; and R4 represents a C1-C6 alkyl group, and so on.

Heterocyclic compound having oxime group

The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I) [where R1 and R2 independently represent a C1-6 alkyl group and the like that may have a hydrogen atom or a substituent; R3 represents a C1-6 alkyl group and the like that may have a substituent; R4 and R5 independent represents a hydrogen atom or a C1-6 alkyl group and the like that may have a substituent; R6 represents a hydrogen atom and the like; W represents —SO2— and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.